If drugmakers have to give up on hard switches, they may have Actavis ($ACT) to thank. Last week, a New York judge called a halt on the company's plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release version. On Monday, the judge nixed Actavis' attempt to block the injunction--and analysts started talking about a precedent. More from FiercePharmaMarketing